Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q4 2015 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derived— vs Q4 2014 Net Income-$1.03M-$1.03Mderivedno prior Q4 2014 on file EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$1,033,194N/M Operating Cash Flowderived-$641,827N/M ended Dec 31, 2015 · filed Feb 1, 2016 · 32 d after period end